From $0 to $300M+ in Sales: Mirum Pharmaceuticals (MIRM)’s Wild Ride Is Just Beginning
Mirum Pharmaceuticals (NASDAQ:MIRM) continues to intrigue growth-focused investors despite trading at a relatively low price-to-sales (P/S) ratio of…
Browsing Tag